Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
Exdensur : Révolution dans le traitement de l'asthme sévère éosinophilique, avec des doses bi-annuelles ultra-longues. Basé sur les essais SWIFT, ce premier et unique biologique réduit significativement les exacerbations annuelles, y compris les hospitalisations et visites aux urgences, offrant une solution vitale pour les 2 millions d'Américains touchés, dont 50 % souffrent de crises récurrentes.
GSK - 17 Déc 2025
Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype
Approval based on SWIFT trials showing significantly lower rate of annualised asthma exacerbations in patients receiving depemokimab versus placebo
SWIFT data included reduction in exacerbations requiring hospitalisation and/or emergency department visits with depemokimab
An estimated 2 million Americans live with severe asthma and 50% continue to experience frequent exacerbations and hospitalisations requiring novel solutions
Approval based on SWIFT trials showing significantly lower rate of annualised asthma exacerbations in patients receiving depemokimab versus placebo
SWIFT data included reduction in exacerbations requiring hospitalisation and/or emergency department visits with depemokimab
An estimated 2 million Americans live with severe asthma and 50% continue to experience frequent exacerbations and hospitalisations requiring novel solutions
